ReviewMethods in molecular biology (Clifton, N.J.)2026
Clinical Development of Bispecific Antibodies: Review, Advances, and Challenges in Hematological Malignancies.
Review in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Three in a bed and changing allogeneic transplant outcomes with a second, non-engrafting cell source.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precision therapies such as monoclonal antibodies (mAbs), immune-checkpoint inhibitors (ICIs), and chimeric antigen receptor T (CAR T)-cell therapies have revolutionized the treatment of cancer. Of these, bispecific antibodies (bsAbs) are gaining attention for their ability to simultaneously target two distinct molecular antigens, aimed at engaging T cells to circumvent cancer immune evasion mechanisms, resulting in tumor cytolysis. Several bsAbs have now been approved in the United States, Europe, and Japan for the treatment of hematological malignancies, most of which are CD3-redirecting bsAbs, although other immune-activating mechanisms are also being explored. This chapter reviews bsAbs in clinical development for hematological malignancies, their basic structure and mechanism of action, and efficacy and safety results of the most advanced bsAbs under clinical investigation.
Indexed as
Identifiers
42108355What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.